Our Pricing

Your Complete Guide to Mounjaro NHS Criteria

Understanding mounjaro nhs criteria uk 2025 is essential if you're considering this treatment for weight management. Mounjaro (tirzepatide) is now available through NHS specialist weight management services under strict eligibility criteria, though private prescription options at Cured Pharmacy offer an alternative pathway with transparent pricing and faster access for those who don't meet NHS thresholds.

Current NHS Eligibility Criteria for Mounjaro

The NHS currently prescribes Mounjaro through specialist weight management services following NICE guidance published in 2023. To qualify for NHS-funded Mounjaro, adults must have a BMI of 35 kg/m² or above (or 32.5 kg/m² for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background) alongside at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1].

Additionally, NHS prescribing requires documented evidence of previous weight management attempts through diet, exercise, and behavioural interventions. Patients must also be enrolled in a specialist tier 3 weight management programme, which typically involves regular monitoring by dietitians, psychologists, and specialist nurses over 12-24 months [2].

NICE guidance specifies that Mounjaro should be discontinued if patients fail to achieve at least 5% weight loss after six months of treatment at the maximum tolerated dose. This outcome-based approach ensures NHS resources are allocated to those most likely to benefit from long-term therapy [1].

BMI Thresholds and Ethnicity Adjustments

The NHS applies lower BMI thresholds for certain ethnic groups who face increased metabolic risk at lower body weights. People of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background qualify at BMI 32.5 kg/m² rather than 35 kg/m², reflecting evidence that these populations develop obesity-related complications at lower BMI levels [2].

These adjusted thresholds align with guidance from Public Health England and the Royal College of Physicians, recognising that standard BMI cut-offs underestimate health risks in these populations. Your GP or specialist service will apply the appropriate threshold based on your family background during initial assessment.

How Mounjaro Works: Dual GIP/GLP-1 Mechanism

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA in the UK. Unlike single-pathway treatments such as semaglutide, tirzepatide activates two complementary hormone systems that regulate appetite, food intake, and glucose metabolism [3].

In the landmark SURMOUNT-1 trial, participants receiving the 15mg maintenance dose of tirzepatide achieved an average 22.5% body weight reduction over 72 weeks, compared to 2.4% with placebo. This represents significantly greater weight loss than observed with semaglutide 2.4mg in head-to-head comparisons [3][4].

The dual mechanism appears to produce superior glycaemic control and weight loss outcomes whilst maintaining a similar side effect profile to single GLP-1 agonists. Most patients experience mild to moderate gastrointestinal symptoms during dose escalation, which typically resolve within 4-8 weeks as tolerance develops [3].

NHS Waiting Times vs Private Prescription Access

Current NHS waiting times for specialist weight management services vary significantly by region, with some areas reporting 12-18 month waits for initial tier 3 assessment appointments. Even after assessment, additional waiting periods apply before Mounjaro prescribing can commence, meaning total time from GP referral to first injection may exceed two years in some NHS trusts.

Private prescription through UK-registered online pharmacies like Cured Pharmacy offers an alternative pathway for patients who don't meet NHS criteria or prefer faster access. Our service includes a free online consultation with a UK prescriber, typically completed within 24-48 hours, followed by discreet home delivery of genuine UK-licensed medication.

All prescription medications dispensed by Cured Pharmacy require clinical assessment by our UK-registered prescribers, who evaluate your medical history, current medications, and suitability for treatment. Superintendent Pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure patient safety and regulatory compliance.

Private Prescription Eligibility Criteria

Private prescribers typically follow similar clinical criteria to NHS guidance but may exercise greater flexibility for patients who fall just outside NHS thresholds. Most UK prescribers require a BMI of 30 kg/m² or above (or 27 kg/m² with weight-related comorbidities) for Mounjaro prescribing, though individual assessment determines final suitability.

Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding. Your prescriber will review your full medical history during consultation to identify any safety concerns that may preclude treatment [3].

Mounjaro Dosing Schedule and Treatment Duration

Mounjaro treatment follows a graduated dose escalation schedule designed to minimise gastrointestinal side effects whilst optimising therapeutic response. All patients begin with 2.5mg once weekly for four weeks, then increase to 5mg weekly for a further four weeks. Subsequent dose increases to 7.5mg, 10mg, 12.5mg, and finally 15mg occur at four-week intervals, subject to tolerability and clinical response [3].

The maximum maintenance dose is 15mg once weekly, though many patients achieve their weight loss goals at lower doses. Your prescriber will determine the optimal maintenance dose based on your individual response, side effect profile, and weight loss trajectory over the first 6-12 months of treatment.

NICE guidance recommends reviewing treatment continuation at six months, with discontinuation considered if weight loss is less than 5% of baseline body weight. However, private prescribers may apply more individualised criteria, considering factors such as improvements in metabolic markers, quality of life, and patient preference when determining treatment duration [1][2].

Cost Comparison: NHS vs Private Mounjaro Prescriptions

NHS prescriptions for Mounjaro incur only the standard prescription charge (currently £135.00 per item in England, free in Scotland, Wales, and Northern Ireland for eligible patients). However, access remains limited to those meeting strict eligibility criteria and enrolled in specialist tier 3 services, with significant regional variation in availability.

Private prescription costs reflect the full medication price plus consultation and dispensing fees. At Cured Pharmacy, Mounjaro is available with transparent upfront pricing and no hidden fees. Our prices remain competitive with other UK pharmacies whilst guaranteeing genuine UK-licensed medication dispensed by our GPhC-registered pharmacy.

When comparing costs, consider the total pathway: NHS prescribing requires ongoing tier 3 programme participation (typically 12-24 months), regular clinic appointments, and potential travel costs. Private prescription offers greater convenience with home delivery and remote monitoring, though patients bear the full medication cost throughout treatment.

Payment Plans and Subscription Options

Many UK online pharmacies, including Cured Pharmacy, offer flexible payment options for ongoing weight loss treatment. Monthly subscription models can help spread costs whilst ensuring treatment continuity without gaps that may compromise efficacy. All payments are processed securely through encrypted payment gateways compliant with UK financial regulations.

Treatment duration varies by individual, with most patients requiring 12-18 months to achieve their target weight loss. Some may transition to maintenance therapy at lower doses or discontinue treatment once stable weight loss is achieved, whilst others may require longer-term therapy to prevent weight regain [4].

Alternative Weight Loss Treatments Available in the UK

Several MHRA-licensed weight loss medications are available through both NHS and private prescription in the UK. Wegovy (semaglutide 2.4mg) is a once-weekly GLP-1 receptor agonist that achieved average weight loss of 14.9% over 68 weeks in the STEP-1 trial, making it an effective alternative for patients who don't tolerate or respond adequately to Mounjaro [4].

Saxenda (liraglutide 3mg) requires daily subcutaneous injection rather than weekly dosing, which some patients find less convenient. Clinical trials demonstrated average weight loss of 8% over 56 weeks with Saxenda, positioning it as a moderate-efficacy option for patients preferring daily dosing or those with contraindications to newer agents [5].

Oral medications including orlistat (available as prescription Xenical 120mg or over-the-counter Alli 60mg) work through a different mechanism by blocking dietary fat absorption. Orlistat produces modest weight loss of approximately 3-5% when combined with calorie restriction, making it suitable for patients who prefer oral therapy or have contraindications to injectable treatments [6].

Choosing the Right Treatment for Your Circumstances

Your choice of weight loss medication depends on multiple factors including your BMI, medical history, previous treatment responses, injection tolerance, and personal preferences regarding dosing frequency. UK prescribers will conduct a comprehensive assessment to recommend the most appropriate option for your individual circumstances.

At Cured Pharmacy, our clinical team provides personalised treatment recommendations following your free online consultation. We stock the full range of UK-licensed weight loss medications, allowing your prescriber to select the optimal therapy without restriction. All consultations are conducted by UK-registered prescribers with expertise in obesity medicine and metabolic health.

Scientific References

1. National Institute for Health and Care Excellence. (2023). Tirzepatide for managing overweight and obesity [TA1102]. NICE. https://www.nice.org.uk/guidance/ta1102
2. NHS England. (2024). Clinical Commissioning Policy: Specialist weight management services (tier 3). NHS England. https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-e/e05/
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Mounjaro is a prescription-only medication that must be prescribed following consultation with a qualified healthcare professional. Always consult your GP or specialist before starting any new weight loss treatment. Individual results may vary, and the clinical data referenced reflects average outcomes in controlled trial settings.